Quinn Opportunity Partners’s Heron Therapeutics HRTX Stock Holding History

Quinn Opportunity Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$74.8K	Hold	175,344	–	–	﹤0.01%	349
2026 Q1	$140K	Hold	175,344	–	–	0.01%	337
2025 Q4	$228K	Hold	175,344	–	–	0.01%	325
2025 Q3	$221K	Hold	175,344	–	–	0.02%	278
2025 Q2	$363K	Sell	175,344 -104,656	-37%	-$214K	0.03%	264
2025 Q1	$616K	Sell	280,000 -100,000	-26%	-$194K	0.04%	254
2024 Q4	$581K	Buy	+380,000	New	+$616K	0.04%	250
2024 Q2	–	Sell	-72,097	Closed	-$200K	–	299
2024 Q1	$200K	Hold	72,097	–	–	0.02%	214
2023 Q4	$123K	Hold	72,097	–	–	0.01%	213
2023 Q3	$74.3K	Hold	72,097	–	–	0.01%	218
2023 Q2	$83.6K	Sell	72,097 -20,000	-22%	-$35.7K	0.01%	195
2023 Q1	$139K	Buy	+92,097	New	+$231K	0.01%	212

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Quinn Opportunity Partners's HRTX Position: Q2 2026 in Review

Quinn Opportunity Partners held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 175,344 shares worth $74.8K. The position accounts for ﹤0.01% of the portfolio, ranked #349.

Quinn Opportunity Partners first reported a position in HRTX in Q1 2023 and has held it in 12 quarters since. The position peaked at $616K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Quinn Opportunity Partners held 175,344 shares of Heron Therapeutics worth $74.8K as of Q2 2026.
Quinn Opportunity Partners left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of Quinn Opportunity Partners's portfolio in Q2 2026, its #349 holding.
Quinn Opportunity Partners first reported a position in Heron Therapeutics in Q1 2023 and has held it in 12 quarters since.
Quinn Opportunity Partners's Heron Therapeutics position peaked at $616K in Q1 2025.
163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.